Literature DB >> 36101481

C-Reactive Protein/Albumin Ratio at Diagnosis of Pediatric Inflammatory Bowel Disease: A Retrospective Multi-Center Study.

Aleksandra Glapa-Nowak1, Mariusz Szczepanik1, Aleksandra Banaszkiewicz2, Jarosław Kwiecień3, Anna Szaflarska-Popławska4, Urszula Grzybowska-Chlebowczyk5, Marcin Osiecki6, Jarosław Kierkuś6, Marcin Dziekiewicz2, Jarosław Walkowiak1.   

Abstract

BACKGROUND This study aimed to evaluate the C-reactive protein-to-albumin (CRP/albumin) ratio at diagnosis of pediatric inflammatory bowel disease (IBD). MATERIAL AND METHODS Serum CRP/albumin ratio was calculated for patients with Crohn's disease (CD; n=186) and ulcerative colitis (UC; n=159) aged 3-18 years. RESULTS Patients with CD differed in CRP/albumin ratio at diagnosis in groups with quiescent, mild, moderate, and severe disease (P=0.011). CRP/albumin ratio at diagnosis was significant in differentiating patients with severe CD from quiescent disease at diagnosis (area under the curve (AUC)=0.94, odds ratio (OR)=63.4, 95% confidence interval (CI) 7.1-569.1, P<0.0001). CRP/albumin ratio at diagnosis could moderately differentiate penetrating from non-penetrating disease behavior in CD at diagnosis (AUC=0.73, OR=6.3, 95% CI 2.0-19.3, P<0.001). Furthermore, CRP/albumin ratio at diagnosis weakly differentiated IBD patients in need of biological treatment in a step-up procedure (AUC=0.58, OR=2.1, 95% CI 1.3-3.4, P=0.022) and in need of surgery (AUC=0.63, OR=3.1, 95% CI 1.4-7.2, P=0.006). For the IBD, CRP/albumin ratio at diagnosis was weakly correlated with age at first immunosuppressive treatment (rho=0.20, P=0.018), time from diagnosis to first biological treatment (rho=-0.37, P<0.001), days spent in hospital (rho=0.26, P=0.007), number of severe relapses (rho=0.31, P=0.001), and Pediatric Crohn's Disease Activity Index (rho=0.38, P=0.002). CONCLUSIONS The present findings add to previous studies carried out in adult patients and show that the CRP/albumin ratio at diagnosis was not significantly associated with the course of either CD or UC in children. However, CRP/albumin ratio could differentiate patients with severe CD from those with quiescent disease.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36101481      PMCID: PMC9484282          DOI: 10.12659/MSM.937842

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  50 in total

1.  C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both? A systematic evaluation in pediatric ulcerative colitis.

Authors:  Dan Turner; David R Mack; Jeffrey Hyams; Neal LeLeiko; Anthony Otley; James Markowitz; Yair Kasirer; Aleixo Muise; Cynthia H Seow; Mark S Silverberg; Wallace Crandall; Anne M Griffiths
Journal:  J Crohns Colitis       Date:  2011-06-02       Impact factor: 9.071

2.  Evaluation of the pediatric crohn disease activity index: a prospective multicenter experience.

Authors:  Jeffrey Hyams; James Markowitz; Anthony Otley; Joel Rosh; David Mack; Athos Bousvaros; Subra Kugathasan; M Pfefferkorn; Vasundhara Tolia; Jonathan Evans; William Treem; Robert Wyllie; Robert Rothbaum; J del Rosario; Aubrey Katz; Adam Mezoff; M Oliva-Hemker; Trudy Lerer; Anne Griffiths
Journal:  J Pediatr Gastroenterol Nutr       Date:  2005-10       Impact factor: 2.839

3.  Defining Severity in Inflammatory Bowel Disease.

Authors:  Laurent Peyrin-Biroulet
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-07

4.  Drug Policy in Poland.

Authors:  Karina Jahnz-Różyk; Pawel Kawalec; Krzysztof Malinowski; Katarzyna Czok
Journal:  Value Health Reg Issues       Date:  2017-09

Review 5.  Challenges in IBD Research: Precision Medicine.

Authors:  Lee A Denson; Mark Curran; Dermot P B McGovern; Walter A Koltun; Richard H Duerr; Sandra C Kim; R Balfour Sartor; Francisco A Sylvester; Clara Abraham; Edwin F de Zoeten; Corey A Siegel; Richéal M Burns; Angela M Dobes; Nataly Shtraizent; Gerard Honig; Caren A Heller; Andrés Hurtado-Lorenzo; Judy H Cho
Journal:  Inflamm Bowel Dis       Date:  2019-05-16       Impact factor: 5.325

6.  Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study.

Authors:  Dan Turner; Anthony R Otley; David Mack; Jeffrey Hyams; J de Bruijne; Krista Uusoue; Thomas D Walters; Mary Zachos; Petar Mamula; Dorcas E Beaton; A Hillary Steinhart; Anne M Griffiths
Journal:  Gastroenterology       Date:  2007-05-21       Impact factor: 22.682

7.  Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines.

Authors:  Dan Turner; Arie Levine; Johanna C Escher; Anne M Griffiths; Richard K Russell; Axel Dignass; Jorge Amil Dias; Jiri Bronsky; Christian P Braegger; Salvatore Cucchiara; Lissy de Ridder; Ulrika L Fagerberg; Séamus Hussey; Jean-Pierre Hugot; Sanja Kolacek; Kaija Leena Kolho; Paolo Lionetti; Anders Paerregaard; Alexander Potapov; Risto Rintala; Daniela E Serban; Annamaria Staiano; Brian Sweeny; Gigi Veerman; Gabor Veres; David C Wilson; Frank M Ruemmele
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-09       Impact factor: 2.839

8.  Serum C-reactive protein and CRP genotype in pediatric inflammatory bowel disease: influence on phenotype, natural history, and response to therapy.

Authors:  Paul Henderson; Nicholas A Kennedy; Johan E Van Limbergen; Fiona L Cameron; Jack Satsangi; Richard K Russell; David C Wilson
Journal:  Inflamm Bowel Dis       Date:  2015-03       Impact factor: 7.290

9.  Platelet-to-lymphocyte Ratio and Neutrophil-to-lymphocyte Ratio Predict Mucosal Disease Severity in Ulcerative Colitis.

Authors:  Muhammet Yener Akpinar; Yasemin Ozderin Ozin; Mustafa Kaplan; Ihsan Ates; Ismail Hakki Kalkan; Zeki Mesut Yalın Kilic; Mahmut Yuksel; Ertugrul Kayacetin
Journal:  J Med Biochem       Date:  2018-04-01       Impact factor: 3.402

10.  A practical marker to determining acute severe ulcerative colitis: CRP/albumin ratio.

Authors:  Suleyman Sayar; Kemal Kurbuz; Resul Kahraman; Zuhal Caliskan; Roni Atalay; Oguzhan Ozturk; Hamdi Levent Doganay; Kamil Ozdil
Journal:  North Clin Istanb       Date:  2019-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.